Corbus Pharmaceuticals to Present at the 2025 RBC Capital Markets Global Healthcare Conference

Company Overview - Corbus Pharmaceuticals Holdings, Inc. is focused on oncology and obesity, with a diversified portfolio aimed at addressing serious illnesses through innovative scientific approaches [2] - The company's pipeline includes CRB-701, a next-generation antibody drug conjugate targeting Nectin-4 on cancer cells; CRB-601, an anti-integrin monoclonal antibody blocking TGFβ activation; and CRB-913, a CB1 receptor inverse agonist for obesity treatment [2] Event Participation - Yuval Cohen, Ph.D., CEO of Corbus, will participate in a fireside chat and one-on-one investor meetings at the 2025 RBC Capital Markets Global Healthcare Conference on May 20-21, 2025 [1][2] - The conference will take place in New York, NY, with the fireside chat scheduled for May 21, 2025, at 8:30 a.m. ET [2]